Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges

Adeia earnings missed by $0.01, revenue fell short of estimates

Author3 weeks ago 0

Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses

Author3 weeks ago 0

Client Challenge

Author3 weeks ago 0

Client Challenge

Author3 weeks ago 0